Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros








Intervalo de ano de publicação
1.
PLoS One ; 13(4): e0195867, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29668768

RESUMO

The purpose of this study was to compare cardiovascular and respiratory effects of two volumes of bupivacaine 0.25% (0.2 mL kg-1-treatment BUP02-and 0.4 mL kg-1 -treatment BUP04) administered epidurally at the lumbosacral intervertebral space in dogs anesthetized with isoflurane. This experimental prospective randomized crossover design trial used six mixed breed adult dogs, four neutered males and two spayed females. Each dog was anesthetized on three different occasions: the first for isoflurane minimum alveolar concentration (MAC) measurement, and the following two assigned treatments (BUP02 or BUP04). On the two treatment days, anesthesia was induced and maintained with isoflurane at 1.3 MAC during the experiments. Cardiovascular and respiratory measurements were recorded before (T0) and 5, 15, 30, 60 and 90 minutes after the epidural administration of bupivacaine. Comparisons between and within groups were performed by a mixed-model ANOVA and Friedman's test when appropriate followed by Bonferroni post-hoc test or Dunnet's test to compare time points within each treatment with T0 (p < 0.05). Mean arterial pressure decreased significantly from 15 to 90 minutes after the administration of BUP02 and from 5 to 60 minutes in BUP04, with lower values in BUP04 than in BUP02 lasting up to 30 minutes after bupivacaine administration. No significant changes in cardiac output and systemic vascular resistance were observed in either treatment. Hypoventilation was only detected in BUP04. Hemoglobin concentration and arterial oxygen content decreased after both treatment of bupivacaine with no significant decrease in oxygen delivery. Two dogs in BUP04 developed Horner's syndrome. The epidural administration of 0.4 mL.kg-1 of bupivacaine to dogs in sternal recumbency anesthetized with isoflurane 1.3 MAC caused more cardiovascular and respiratory depression than 0.2 mL.kg-1.


Assuntos
Anestésicos Inalatórios/farmacologia , Anestésicos Locais/farmacologia , Bupivacaína/farmacologia , Sistema Cardiovascular/efeitos dos fármacos , Isoflurano/farmacologia , Respiração/efeitos dos fármacos , Anestesia Epidural , Animais , Pressão Sanguínea/efeitos dos fármacos , Cães , Feminino , Masculino , Testes de Função Respiratória
2.
Int J Exp Pathol ; 98(5): 269-277, 2017 10.
Artigo em Inglês | MEDLINE | ID: mdl-29205609

RESUMO

End-to-end anastomosis in the treatment for bile duct injury during laparoscopic cholecystectomy has been associated with stricture formation. The aim of this study was to experimentally investigate the effect of oral tamoxifen (tmx) treatment on fibrosis, collagen content and transforming growth factor-ß1, -ß2 and -ß3 expression in common bile duct anastomosis of pigs. Twenty-six pigs were divided into three groups [sham (n = 8), control (n = 9) and tmx (n = 9)]. The common bile ducts were transected and anastomosed in the control and tmx groups. Tmx (40 mg/day) was administered orally to the tmx group, and the animals were euthanized after 60 days. Fibrosis was analysed by Masson's trichrome staining. Picrosirius red was used to quantify the total collagen content and collagen type I/III ratio. mRNA expression of transforming growth factor (TGF)-ß1, -ß2 and -ß3 was quantified using real-time polymerase chain reaction (qRT-PCR). The control and study groups exhibited higher fibrosis than the sham group, and the study group showed lower fibrosis than the control group (P = 0.011). The control and tmx groups had higher total collagen content than the sham group (P = 0.003). The collagen type I/III ratio was higher in the control group than in the sham and tmx groups (P = 0.015). There were no significant differences in the mRNA expression of TGF-ß1, -ß2 and -ß3 among the groups (P > 0.05). Tmx decreased fibrosis and prevented the change in collagen type I/III ratio caused by the procedure.


Assuntos
Anastomose Cirúrgica/efeitos adversos , Colágeno/metabolismo , Ducto Colédoco/patologia , Ducto Colédoco/cirurgia , Tamoxifeno/uso terapêutico , Fator de Crescimento Transformador beta/biossíntese , Animais , Ducto Colédoco/lesões , Ducto Colédoco/metabolismo , Avaliação Pré-Clínica de Medicamentos/métodos , Fibrose , Masculino , RNA Mensageiro/genética , Sus scrofa , Tamoxifeno/farmacologia , Fator de Crescimento Transformador beta/genética , Fator de Crescimento Transformador beta1/biossíntese , Fator de Crescimento Transformador beta1/genética , Fator de Crescimento Transformador beta2/biossíntese , Fator de Crescimento Transformador beta2/genética , Fator de Crescimento Transformador beta3/biossíntese , Fator de Crescimento Transformador beta3/genética , Cicatrização/efeitos dos fármacos
3.
Clinics (Sao Paulo) ; 68(1): 101-6, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23420165

RESUMO

OBJECTIVE: The aim of this study was to evaluate the effect of oral tamoxifen treatment on the number of myofibroblasts present during the healing process after experimental bile duct injury. METHODS: The sample consisted of 16 pigs that were divided into two groups (the control and study groups). Incisions and suturing of the bile ducts were performed in the two groups. Tamoxifen (20 mg/day) was administered only to the study group. The animals were sacrificed after 30 days. Quantification of myofibroblasts in the biliary ducts was made through immunohistochemistry analysis using anti-alpha smooth muscle actin of the smooth muscle antibody. Immunohistochemical quantification was performed using a digital image system. RESULTS: In the animals treated with tamoxifen (20 mg/day), there was a significant reduction in immunostaining for alpha smooth muscle actin compared with the control group (0.1155 vs. 0.2021, p = 0.046). CONCLUSION: Tamoxifen reduced the expression of alpha smooth muscle actin in the healing tissue after bile duct injury, suggesting a decrease in myofibroblasts in the scarred area of the pig biliary tract. These data suggest that tamoxifen could be used in the prevention of biliary tract stenosis after bile duct surgeries.


Assuntos
Ductos Biliares/lesões , Antagonistas de Estrogênios/uso terapêutico , Miofibroblastos/efeitos dos fármacos , Tamoxifeno/uso terapêutico , Cicatrização/efeitos dos fármacos , Actinas/análise , Actinas/efeitos dos fármacos , Animais , Ductos Biliares/efeitos dos fármacos , Contagem de Células , Feminino , Imuno-Histoquímica , Músculo Liso/química , Músculo Liso/efeitos dos fármacos , Reprodutibilidade dos Testes , Suínos , Resultado do Tratamento
4.
Clinics ; 68(1): 101-106, Jan. 2013. ilus, tab
Artigo em Inglês | LILACS | ID: lil-665925

RESUMO

OBJECTIVE: The aim of this study was to evaluate the effect of oral tamoxifen treatment on the number of myofibroblasts present during the healing process after experimental bile duct injury. METHODS: The sample consisted of 16 pigs that were divided into two groups (the control and study groups). Incisions and suturing of the bile ducts were performed in the two groups. Tamoxifen (20 mg/day) was administered only to the study group. The animals were sacrificed after 30 days. Quantification of myofibroblasts in the biliary ducts was made through immunohistochemistry analysis using anti-alpha smooth muscle actin of the smooth muscle antibody. Immunohistochemical quantification was performed using a digital image system. RESULTS: In the animals treated with tamoxifen (20 mg/day), there was a significant reduction in immunostaining for alpha smooth muscle actin compared with the control group (0.1155 vs. 0.2021, p = 0.046). CONCLUSION: Tamoxifen reduced the expression of alpha smooth muscle actin in the healing tissue after bile duct injury, suggesting a decrease in myofibroblasts in the scarred area of the pig biliary tract. These data suggest that tamoxifen could be used in the prevention of biliary tract stenosis after bile duct surgeries.


Assuntos
Animais , Feminino , Ductos Biliares/lesões , Antagonistas de Estrogênios/uso terapêutico , Miofibroblastos/efeitos dos fármacos , Tamoxifeno/uso terapêutico , Cicatrização/efeitos dos fármacos , Actinas/análise , Actinas/efeitos dos fármacos , Ductos Biliares/efeitos dos fármacos , Contagem de Células , Imuno-Histoquímica , Músculo Liso/química , Músculo Liso/efeitos dos fármacos , Reprodutibilidade dos Testes , Suínos , Resultado do Tratamento
5.
Rev. bras. ciênc. vet ; 8(3): 151-154, set.-dez. 2001. tab
Artigo em Português | LILACS | ID: lil-319109

RESUMO

O presente estudo teve como objetivo avaliar alteraçöes na pressäo arterial média (PAM) com uso de bupivacaína hiperbárica 0,5 por cento (0,3 mg.kg(-1)) no espaço subaracnóide de cäes. Foram utilizados seis animais, fêmeas, sem raça definida, na faixa etária entre um a cinco anos, hígidas e com peso variando entre sete e 15 kg. Após a contençäo mecânica dos animais foi realizada a punçäo do ramo cranial da artéria safena com o intuito da aferiçäo basal da pressäo arterial média (PAM). Os animais foram pré-oxigenados com O2 a 100 por cento (3 L/min) durante 5 minutos, induzidos com propofol (6 mg/kg) e, após a perda dos reflexos protetores, foi realizada a segunda aferiçäo da PAM. A terceira mensuraçäo da PAM procedeu-se após a intubaçäo orotraqueal. Os animais foram monitorados e mantidos através de infusäo contínua de propofol (0,5mg.kg(-1).min) e a PAM mensurada durante 15 minutos em intervalos de 5 minutos. Posteriormente, foram realizadas a anti-sepsia e assepsia da regiäo lombossacra e o espaço subaracnóide puncionado (L6-L7), para administraçäo de bupivacaína (0.3 mg.kg(-1)). Uma vez constatado o bloqueio, a PAM foi mensurada durante um período de uma hora, com intervalos de 5 minutos. Como conclusäo deste estudo näo observamos nenhum valor pressórico compatível com um quadro hipotensivo.


Assuntos
Animais , Feminino , Cães , Anestésicos Locais/farmacologia , Raquianestesia , Bupivacaína/farmacologia , Pressão Arterial , Anestésicos Intravenosos , Propofol
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA